- Target disease: Leishmaniasis
- Main partners (since project start): Drug Discovery Unit, University of Dundee, UK; GlaxoSmithKline (GSK), Spain.
- Project start: 2017
- Funding (since project start): Department for International Development (DFID), UK; Dutch Ministry of Foreign Affairs (DGIS), The Netherlands; Federal Ministry of Education and Research (BMBF through KfW), Germany; Médecins Sans Frontières/Doctors without Borders, International; Swiss Agency for Development and Cooperation (SDC), Switzerland.
In April 2017, DNDi and GSK entered into an agreement for the pre-clinical development of two compounds for leishmaniasis which were discovered by GSK in collaboration with the Drug Discovery Unit (DDU) at the University of Dundee, following some co-funding by the Wellcome Trust.
A Phase I study with the compound GSK3186899/DDD853651 is expected to start in April 2019 following appropriate regulatory and ethical approvals and will be conducted by GSK. GSK3494245/DDD1305143 is currently under review to assess the feasibility of proceeding to a Phase I study.
Last update: February 2019